Clinical Trial Update: Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer [NA]

View source ↗

Summary

Completed single-center, single-arm study evaluating the safety and efficacy of the radiopharmaceutical 177Lu-LNC1011 in PSMA PET-positive metastatic castration…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 177Lu-LNC1011

Snippet

Sponsor: Affiliated Hospital of Jiangnan University | Conditions: PSMA PET-Positive Castration-Resistant Prostate Cancer | NA | Status: COMPLETED